LANREOTIDE ACETATE Recalls

Cipla USA Lanreotide Injection Recall for Sterility Assurance Issue (2026)

Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.

Lanreotide Injection recall: Cipla USA lanreotide acetate pre-filled syringes recalled for sterility

Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.

Cipla Lanreotide Acetate Injection Recall: 15,221 Syringes Over Particulate Matter (2026)